It also represents the first attempt to determine the impact of PD-L1 antibodies, alone or in combination with BRAF inhibitor, on tumor volume in an in vivo immunocompetent murine model of anaplastic thyroid cancer. The gene discussed is BRAF; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.